her disease and based on a recently published small case series. The success of rituximab was evident by the cessation of further corneal thinning and ability to cease systemic steroids over the last 12 months.
Background: Minimum biodrug concentrations of ≈7 mg/L are predictive of disease remission although there is no consensus on therapeutic drug levels. Very low biodrug concentrations associate with loss of benefit in may be due to ADA. Canterbury Health Laboratories, New Zealand (CHL) has developed a competitive binding ELISA to detect neutralising antibodies whereas most commercial assays utilise a bridging methodology.
Methods: Serum samples with low/absent drug concentration defined as <1 mg/L of Infliximab/Adalimumab were tested for ADA using three different methods; the competitive-binding ELISA, the IgG4 ELISA and bridging ELISA. Detection target of the three assays were the reduction of IgG Fc of the drug bound to TNF, bivalent IgG Fab of the ADA and IgG4 Fc of the ADA respectively.
Results: 15.2% (76/497) of referred samples had low/absent concentrations <1 mg/L (adalimumab n = 33 or infliximab n = 43). The competitive binding assay detected ADAs in 44.3% (35/76), bridging assay 35.5% (27/76) and IgG4 ELISA 52.6% (40/76). The bridging ELISA was the least sensitive with all the positive results picked up by the competitive ELISA. The IgG4 ELISA detected an additional 14/76 not picked up by the competitive ELISA. These 14 samples may contain monovalent IgG4 that does not crosslink ADA affecting the performance of our competitive assay. Overall ADAs were detected in 64.5% (49/76) of samples with low/-absent drug concentrations.
Conclusion:
The clinical utility of ADA is assay dependent. The commercial bridging assay is the least sensitive of the three methods used and underestimates the frequency of ADA in serum samples of patients undertaking treatment anti-TNF agents with low/absent drug concentrations (<1 mg/L). With the use of the competitive assay and IgG4 ELISA, the detection of ADA would almost double that of bridging assay alone in our patient cohort. Four patients (three CSU and one idiopathic angioedema) in whom stress was a recognised trigger, were consented and recruited into a brief whole person treatment approach (WPTA) based in non-dualistic concepts of mind and body connectedness, for up to 10 × 1 h long sessions. A mixed methods Grounded Theory and Interpretive Phenomenology Analysis of data derived from these patients were used to explore patients' experience of Mind-Body connection in CSU.
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Treatment efficacy rating, using Urticaria Activity Score and the Urticaria Severity Score, and drug usage, showed patients experienced long term resolution of urticarial up to 2 years, and came off regular antihistamine medication. Patients developed chronic urticarial or angioedema in the context of a uniquely meaningful extra-ordinary life experience which overwhelmed the persons personal and relational ability to process it. During the WPTA patients reflected on the meaning of symptoms, process the experience and changed their 'way of being in relation to themselves and others', and their symptoms resolved or improved. Selected CSU patients can be successfully treated using a non-dualistic WPTA. Both qualitative and quantitative data will be presented. A larger study comparing the outcome, cost effectiveness and quality of life of WPTA versus standard treatment alone is warranted. Case report: We report a 17-year-old boy who presented at 6 months of age with persistence stridor and cough and a diagnosis of RRP -HPV-11 was made. Symptoms progressed and by 10 months laser microlaryngoscopy was required. In total he has had over 130 admissions to our hospital with over 80 surgical procedures. By 12 years the disease was affecting the trachea (70% obstruction), larynx and right main bronchus. By 13 years the disease was involving lung parenchyma with multiple cystic lesions seen on CT. He was requiring surgical intervention every 4-6 weeks. All adjuvant treatment modalities had failed to control the disease progression, some with an unacceptable side effect profile, including increased risk of malignancy and renal toxicity. Having exhausted standard treatments palliation was considered.
P91 NOVEL TREATMENT OF RECURRENT RESPIRATORY PAPILLOMATOSIS
Breakthrough treatment: Intralesional bevacizumab (Avastin), a recombinant humanised monoclonal IgG1 antibody that inhibits vascular endothelial growth factor (VEGF-A) by preventing receptor activation, was trialled as salvage therapy. This was followed 6 months later with oral Gefitinib, an epidermal growth factor receptor inhibitor in the tyrosine kinase domain. Both agents have continued. This has resulted in a significant improvement in quality of life and increasing intervals between surgical debridement. Results: 20 patients had definite or probable IgG4RD; median age 59 (20-76), M:F 1.5:1. There was a considerable delay in diagnosis (median diagnosis at 64 months). Organ involvement included: 11 exocrine gland, 7 pancreatobiliary, 7 nodal, 5 retroorbital, 3 retroperitoneal fibrosis and 2 renal. 7 had soft tissue involvement, 1 had pleural disease. Systemic symptoms at diagnosis were seen in 8. 7 (35%) had an elevated serum IgG 4 (>1.35 g/L) at diagnosis. 13 (65%) had >10 IgG4 plasma cells per HPF and 12 (60%) an IgG4:IgG ratio >0.4. More than half of pathology reports did not meet the Boston Criteria. Few had descriptions of storiform fibrosis or obliterative phlebitis. Only half required immunosuppressive treatment. The median duration of follow up was 18 months.
Conclusion
Conclusion: This is the first characterised Australian cohort with IgG4RD, a relatively indolent condition responsive to minimal immunosuppression. Better organ-specific pathology diagnostic criteria are required to capture this rare disease. ImmunoRheumatology Laboratory, New South WalesAustralia
P93 ANTITHYMOCYTE GLOBULIN FOR THE TREATMENT OF CHECKPOINT INHIBITOR MEDIATED MYOCARDITIS

Introduction:
We report the first successful use of rabbit anti-thymocyte globulin (r-ATG) for checkpoint inhibitor-mediated severe, fulminant myocarditis complicated by ventricular tachycardia (VT) storm.
Case report: A 65-year-old female presented hypotensive with conscious VT, 2 weeks after her third anti-PD-1 monoclonal antibody (nivolumab) infusion, which had been started 6 weeks earlier for oesophageal adenocarcinoma.
A troponin (>5000 ng/L) confirmed myocardial injury. A transthoracic echocardiogram showed global systolic impairment (ejection fraction of 35%). Cardio-respiratory investigation excluded pulmonary embolus, and coronary artery disease. No viral aetiology was detected on serology and nasal swab.
The patient's VT storm was variably refractory to IV amiodarone, nebivolol, and IV lignocaine. A transvenous pacing wire was placed and overdrive pacing performed.
Recent literature demonstrated the presence of a lymphocyte predominant infiltrate with T cells in a myocardial biopsy from patients with checkpoint inhibitor-mediated myocarditis. Therapy was commenced with pulsed methylprednisolone 1 g daily for three days.
The patient deteriorated within 24 h requiring intubation and vasopressor support.
In an attempt to deplete the putative pathological myocardial CD3 lymphocyte population, r-ATG was commenced at 1.5 mg/kg with premedication comprising loratadine and hydrocortisone. Plan was made for 3 doses over three days. After the first infusion, VT subsided and did not recur. r-ATG was complicated by severe hypotension. Further dosing was contraindicated. The following day, her total lymphocyte count was 0 cells/L. No further doses of r-ATG were administered and mycophenolate was commenced to maintain control of her disease. Her ejection fraction improved to 50%.
Conclusion: Myocarditis is a rare but serious side effect of checkpoint inhibitor-therapy. The pathophysiology, treatment and prognosis are still being defined. Outcomes in small case series are poor. r-ATG appears to deplete inflammatory T-lymphocytes in the myocardium, and in this case served to abort refractory VT storm.
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